We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial
Read MoreHide Full Article
Key Takeaways
Novocure's Phase 3 PANOVA-3 trial met its primary endpoint with a two-month median survival benefit.
NVCR's TTFields therapy showed higher one-year survival rates than chemotherapy alone in the trial.
Novocure's TTFields improved pain-free survival and quality of life, with favorable safety outcomes.
Novocure (NVCR - Free Report) recently announced positive top-line results from its pivotal Phase 3 PANOVA-3 trial, evaluating Tumor Treating Fields (TTFields) therapy in combination with gemcitabine and nab-paclitaxel for patients with unresectable, locally advanced pancreatic cancer. The study successfully met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) compared to standard chemotherapy alone.
This outcome reinforces TTFields’ potential as a meaningful addition to the pancreatic cancer treatment landscape, offering a non-invasive, well-tolerated option alongside chemotherapy. The PANOVA-3 trial also showed notable survival benefits at both the 12- and 24-month marks, signaling durable clinical efficacy. These findings bolster Novocure’s strategy to expand TTFields’ indications beyond glioblastoma and mesothelioma and lay the groundwork for regulatory submissions in major markets, including the United States, the EU, and Japan.
Likely Trend of NVCR Stock Following the News
Following the announcement on May 31, shares of the company have tumbled 13.9% and closed at $16.45 on Thursday. In the year-to-date period, NVCR’s shares have lost 44.8% compared with the industry’s 3.9% decline. The S&P 500 increased 0.9% in the same time frame.
However, the positive results from the PANOVA-3 trial could significantly boost Novocure’s long-term business prospects by enabling commercial expansion into the pancreatic cancer market, an area with high unmet medical need and limited effective treatment options. Regulatory approvals based on these data would allow TTFields therapy to be adopted as part of the frontline treatment for a broader patient population, driving top-line revenue growth and improving reimbursement prospects globally.
Meanwhile, NVCR currently has a market capitalization of $1.86 billion.
Image Source: Zacks Investment Research
Details on the PANOVA-3 Trial
The PANOVA-3 trial is a global, randomized, open-label Phase 3 study evaluating the efficacy and safety of TTFields therapy in combination with gemcitabine and nab-paclitaxel as a first-line treatment for patients with locally advanced pancreatic adenocarcinoma. A total of 571 patients were enrolled and randomized 1:1 to receive either the TTFields-combination regimen or chemotherapy alone, with each participant followed for at least 18 months.
The trial’s primary endpoint is overall survival, while secondary endpoints include progression-free survival, objective response rate, quality of life, pain- and puncture-free survival, and toxicity, among others, aiming to provide a comprehensive understanding of the therapy’s clinical benefit across multiple dimensions.
More on the Trial’s Positive Data
The PANOVA-3 trial achieved its primary endpoint, showing a statistically significant improvement in median overall survival (mOS) for patients treated with TTFields therapy in combination with gemcitabine and nab-paclitaxel. In the intent-to-treat population of 571 patients, those receiving the TTFields combination achieved an mOS of 16.2 months versus 14.2 months in the control group, reflecting a two-month survival benefit. In addition to mOS, TTFields therapy also demonstrated a significant improvement in one-year survival, with 68.1% of patients alive at one year compared to 60.2% in the chemotherapy-only group. These data mark a meaningful clinical advancement for patients with unresectable, locally advanced pancreatic cancer.
The trial also highlighted notable gains in patient-reported outcomes, particularly in pain management. Median pain-free survival, defined as the time until a significant increase in self-reported pain or death, was 15.2 months in the TTFields group versus 9.1 months in the control arm, representing a statistically significant 6.1-month improvement. Quality of life assessments using the EORTC QLQ-C30 and PAN26 questionnaires showed significant benefits in global health status, pain, and digestive symptoms among patients receiving TTFields therapy.
While other secondary endpoints, such as progression-free survival, local progression-free survival, and tumor resectability, did not show statistically significant differences, the overall safety profile remained favorable. TTFields was well tolerated, with no new safety signals reported, and most device-related adverse events were limited to mild-to-moderate skin reactions.
NVCR’s Zacks Rank & Other Stocks to Consider
NVCR carries a Zacks Rank #2 (Buy) at present.
Some other top-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation (CVS - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and AngioDynamics (ANGO - Free Report) .
Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%.
Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank of 1.
Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%.
AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%.
ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite’s 10.5% growth. AngioDynamics’ earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial
Key Takeaways
Novocure (NVCR - Free Report) recently announced positive top-line results from its pivotal Phase 3 PANOVA-3 trial, evaluating Tumor Treating Fields (TTFields) therapy in combination with gemcitabine and nab-paclitaxel for patients with unresectable, locally advanced pancreatic cancer. The study successfully met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) compared to standard chemotherapy alone.
This outcome reinforces TTFields’ potential as a meaningful addition to the pancreatic cancer treatment landscape, offering a non-invasive, well-tolerated option alongside chemotherapy. The PANOVA-3 trial also showed notable survival benefits at both the 12- and 24-month marks, signaling durable clinical efficacy. These findings bolster Novocure’s strategy to expand TTFields’ indications beyond glioblastoma and mesothelioma and lay the groundwork for regulatory submissions in major markets, including the United States, the EU, and Japan.
Likely Trend of NVCR Stock Following the News
Following the announcement on May 31, shares of the company have tumbled 13.9% and closed at $16.45 on Thursday. In the year-to-date period, NVCR’s shares have lost 44.8% compared with the industry’s 3.9% decline. The S&P 500 increased 0.9% in the same time frame.
However, the positive results from the PANOVA-3 trial could significantly boost Novocure’s long-term business prospects by enabling commercial expansion into the pancreatic cancer market, an area with high unmet medical need and limited effective treatment options. Regulatory approvals based on these data would allow TTFields therapy to be adopted as part of the frontline treatment for a broader patient population, driving top-line revenue growth and improving reimbursement prospects globally.
Meanwhile, NVCR currently has a market capitalization of $1.86 billion.
Image Source: Zacks Investment Research
Details on the PANOVA-3 Trial
The PANOVA-3 trial is a global, randomized, open-label Phase 3 study evaluating the efficacy and safety of TTFields therapy in combination with gemcitabine and nab-paclitaxel as a first-line treatment for patients with locally advanced pancreatic adenocarcinoma. A total of 571 patients were enrolled and randomized 1:1 to receive either the TTFields-combination regimen or chemotherapy alone, with each participant followed for at least 18 months.
The trial’s primary endpoint is overall survival, while secondary endpoints include progression-free survival, objective response rate, quality of life, pain- and puncture-free survival, and toxicity, among others, aiming to provide a comprehensive understanding of the therapy’s clinical benefit across multiple dimensions.
More on the Trial’s Positive Data
The PANOVA-3 trial achieved its primary endpoint, showing a statistically significant improvement in median overall survival (mOS) for patients treated with TTFields therapy in combination with gemcitabine and nab-paclitaxel. In the intent-to-treat population of 571 patients, those receiving the TTFields combination achieved an mOS of 16.2 months versus 14.2 months in the control group, reflecting a two-month survival benefit. In addition to mOS, TTFields therapy also demonstrated a significant improvement in one-year survival, with 68.1% of patients alive at one year compared to 60.2% in the chemotherapy-only group. These data mark a meaningful clinical advancement for patients with unresectable, locally advanced pancreatic cancer.
The trial also highlighted notable gains in patient-reported outcomes, particularly in pain management. Median pain-free survival, defined as the time until a significant increase in self-reported pain or death, was 15.2 months in the TTFields group versus 9.1 months in the control arm, representing a statistically significant 6.1-month improvement. Quality of life assessments using the EORTC QLQ-C30 and PAN26 questionnaires showed significant benefits in global health status, pain, and digestive symptoms among patients receiving TTFields therapy.
While other secondary endpoints, such as progression-free survival, local progression-free survival, and tumor resectability, did not show statistically significant differences, the overall safety profile remained favorable. TTFields was well tolerated, with no new safety signals reported, and most device-related adverse events were limited to mild-to-moderate skin reactions.
NVCR’s Zacks Rank & Other Stocks to Consider
NVCR carries a Zacks Rank #2 (Buy) at present.
Some other top-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation (CVS - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and AngioDynamics (ANGO - Free Report) .
CVS Health, carrying a Zacks Rank of 2, reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%.
Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank of 1.
Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%.
AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%.
ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite’s 10.5% growth. AngioDynamics’ earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%.